CUBIST PHARMS LLC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST PHARMS LLC, and when can generic versions of CUBIST PHARMS LLC drugs launch?
CUBIST PHARMS LLC has six approved drugs.
There are twenty-nine US patents protecting CUBIST PHARMS LLC drugs.
There are three hundred and forty patent family members on CUBIST PHARMS LLC drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for CUBIST PHARMS LLC
International Patents: | 340 |
US Patents: | 29 |
Tradenames: | 5 |
Ingredients: | 4 |
NDAs: | 6 |
Drugs and US Patents for CUBIST PHARMS LLC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 8,426,389 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 8,420,676 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 10,442,829 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 8,426,389 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CUBIST PHARMS LLC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,852,689 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 8,058,238 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | RE39071 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,129,342 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
International Patents for CUBIST PHARMS LLC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Tunisia | 2015000411 | ⤷ Try a Trial |
Japan | 6151257 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008091554 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2005112990 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2010091131 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CUBIST PHARMS LLC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1699784 | CA 2015 00048 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325 |
1556389 | 2015/074 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918 |
1539977 | 122015000026 | Germany | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205 |
1699784 | 243 50021-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325 |
1539977 | 2015/019 | Ireland | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205; FIRST REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.